AJMC® in the Press, March 24, 2023

On November 20, the FDA approved bimekizumab (Bimzelx; UCB Pharma) for use in patients with moderate to severe hidradenitis suppurativa.

The Wellness Way facility was designed to improve access to comprehensive outpatient care and address social determinants of health for a diverse patient population.

Adults with more unfavorable health-related social needs, such as unemployment or food insecurity, had a higher prevalence of low cardiovascular health, highlighting the importance of addressing social determinants to improve population health.

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

The increase in the global burden of interstitial lung disease (ILD) and pulmonary sarcoidosis had the greatest impact on countries with a high sociodemographic index.

The health care policy poster session, “Behind the Curtain: How Healthcare Policy Shapes Patient Outcomes,” took place Monday, November 18, 2024, the final day of the American Heart Association Scientific Sessions.